<DOC>
	<DOCNO>NCT00718159</DOCNO>
	<brief_summary>The purpose study determine safe dose LY573636-sodium give patient acute myeloid leukemia determine side effect may associate LY573636-sodium patient population . Efficacy measure also use assess activity LY573636-sodium acute myeloid leukemia essential thrombocythemia patient .</brief_summary>
	<brief_title>Study LY573636-sodium Essential Thrombocythemia Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Patients diagnosis either essential thrombocythemia acute myeloid leukemia relapse refractory least one prior standard treatment . If patient acute promyelocytic leukemia , must resistant and/or intolerant trans retinoic acid ( ATRA ) arsenic trioxide . Are least 18 year age . Have give write informed consent approve Lilly ethical review board ( ERB ) /institutional review board ( IRB ) govern site . Must adequate hepatic renal function . Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , immunotherapy , cancerrelated hormonal therapy , investigational therapy least 21 day myelosuppressive agent ( cytarabine , daunorubicin , gemtuzumab ozogamicin ) 14 day nonmyelosuppressive agent prior receive study drug recover acute effect therapy . Hydroxyurea use control peripheral blood blast count permit within respective period , must stop least 24 hour study drug administration . Males female reproductive potential must agree use medically approve contraceptive precaution trial 6 month follow last dose study drug . Females child bear potential must negative serum pregnancy test less equal 7 day prior first dose study drug . Have serum albumin level great equal 3.0 g/L , less equal 72 hour prior dose LY573636sodium . Have receive treatment drug receive regulatory approval indication within 14 21 day initial dose study drug nonmyelosuppressive myelosuppressive agent , respectively . Patients myeloproliferative disorder ( example.chronic myeloid leukemia ( CML ) , polycythemia vera primary myelofibrosis ) essential thrombocythemia . Have receive autologous allogenic stem cell transplant within 75 day initial dose study drug dose escalation phase within 60 day initial dose study drug dose confirmation phase . Recipients allogeneic stem cell transplant must discontinue immunosuppressive therapy least 24 hour study drug administration Grade 1 acute graftversushost disease . Have previously complete withdrawn study study investigate LY573636 sodium . Have serious preexist medical condition opinion investigator would preclude participation study . Have serious concomitant disorder , include active bacterial , fungal , viral infection , incompatible study . Have second primary malignancy could effect interpretation result . Have know coagulopathy bleeding disorder , leukemic relate thrombocytopenia . Patients severe lifethreatening bleed refractory platelet transfusion also exclude study . Major surgery within 4 week study enrollment . Are receive warfarin ( Coumadin ) . Females pregnant breast feeding . Have know positive result HIV , hepatitis B surface antigen ( HBSAg ) hepatitis C antibody ( HCAb ) . Have receive treatment within 28 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication . Patients receive amiodarone , quinidine , propofol , clozapine . Patients receive treatment strong moderate inhibitor cytochrome P450 ( CYP ) 2C19 , include protonpump inhibitor ( PPIs ) . Esomeprazole pantoprazole allow administer within 72 hour LY573636 administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myeloid Leukemia</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>